Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 22 07 2021
accepted: 23 11 2021
entrez: 7 12 2021
pubmed: 8 12 2021
medline: 16 12 2021
Statut: epublish

Résumé

The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada's public health policy in response to COVID-19.

Identifiants

pubmed: 34874948
doi: 10.1371/journal.pone.0261003
pii: PONE-D-21-23872
pmc: PMC8651133
doi:

Substances chimiques

Antibodies, Viral 0
Reagent Kits, Diagnostic 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0261003

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Arch Pathol Lab Med. 2021 Jan 1;145(1):32-38
pubmed: 33367664
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Biotechnol. 2020 Oct;38(10):1174-1183
pubmed: 32855547
Microorganisms. 2021 Jan 25;9(2):
pubmed: 33504067
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32870820
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33023911
NPJ Digit Med. 2020 Jul 13;3:95
pubmed: 32695885
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32341142
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
J Clin Virol. 2020 Jul;128:104426
pubmed: 32417674
Am J Clin Pathol. 2020 Oct 13;154(5):610-619
pubmed: 32808976
CMAJ. 2020 Aug 24;192(34):E973-E979
pubmed: 32753391
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Emerg Infect Dis. 2020 Dec;26(12):2970-2973
pubmed: 32969788
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Sci Rep. 2020 Nov 19;10(1):20188
pubmed: 33214612
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Sci Rep. 2021 Apr 8;11(1):7754
pubmed: 33833246
Nat Med. 2021 Jan;27(1):28-33
pubmed: 33442016
BMC Med. 2020 Nov 4;18(1):346
pubmed: 33143712
Cell Rep Med. 2020 Aug 25;1(5):100062
pubmed: 32838340
AAPS J. 2020 Oct 6;22(6):127
pubmed: 33025311
Sci Rep. 2021 May 4;11(1):9475
pubmed: 33947894
PLoS One. 2020 Nov 9;15(11):e0241959
pubmed: 33166373
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
EJIFCC. 2009 Jan 20;19(4):203-11
pubmed: 27683318
Clin Chim Acta. 2020 Oct;509:1-7
pubmed: 32485157
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Lancet. 2020 May 2;395(10234):e79-e80
pubmed: 32334649
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738

Auteurs

François Cholette (F)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Christine Mesa (C)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Angela Harris (A)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Hannah Ellis (H)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Karla Cachero (K)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Philip Lacap (P)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Yannick Galipeau (Y)

Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada.

Marc-André Langlois (MA)

Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada.
The Centre for Infection, Immunity, and Inflammation (CI3), University of Ottawa, Ottawa, Canada.

Anne-Claude Gingras (AC)

Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Canada.

Cedric P Yansouni (CP)

McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, Canada.

Jesse Papenburg (J)

McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, Canada.
Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montréal-McGill University Health Centre, Montréal, Canada.

Matthew P Cheng (MP)

McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, Canada.
Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montréal-McGill University Health Centre, Montréal, Canada.

Pranesh Chakraborty (P)

Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, Canada.

Derek R Stein (DR)

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Cadham Provincial Laboratory, Manitoba Health, Winnipeg, Canada.

Paul Van Caeseele (P)

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Cadham Provincial Laboratory, Manitoba Health, Winnipeg, Canada.
Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Canada.
COVID-19 Immunity Task Force, Montréal, Canada.

Sofia Bartlett (S)

British Columbia Centre for Disease Control, Vancouver, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Mel Krajden (M)

British Columbia Centre for Disease Control, Vancouver, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

David Goldfarb (D)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Allison McGeer (A)

COVID-19 Immunity Task Force, Montréal, Canada.
Division of Infectious Diseases, University of Toronto, Toronto, Canada.

Carla Osiowy (C)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Catherine Hankins (C)

COVID-19 Immunity Task Force, Montréal, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Canada.

Bruce Mazer (B)

Department of Pediatrics, McGill University, Montréal, Canada.

Michael Drebot (M)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

John Kim (J)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH